1	Two founder variants account for over 90% of pathogenic BRCA alleles in Orkney and Shetland
2	
3	Shona M. Kerr ¹ , Lucija Klaric ¹ , Marisa D. Muckian ^{2,3} , Emma Cowan ⁴ , Lesley Snadden ⁴ , Gannie Tzoneva ⁵ ,
4	Alan R. Shuldiner ⁵ , Zosia Miedzybrodzka ^{4,6} and James F. Wilson ^{+1,2,7}
5	
6	¹ MRC Human Genetics Unit, University of Edinburgh, Institute of Genetics and Cancer, Western General
7	Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
8	² Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh EH8
9	9AG, UK
10	³ Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel
11	Street, London WC1E 7HT, UK
12	⁴ Department of Medical Genetics, Ashgrove House, NHS Grampian, Aberdeen, AB25 2ZA, UK
13	⁵ Regeneron Genetics Center, Tarrytown, NY, USA
14	⁶ Medical Genetics Group, University of Aberdeen, Polwarth Building, Aberdeen, AB25 2ZD, UK
15	⁷ Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of
16	Edinburgh, Edinburgh, EH4 2XU, UK
17	
18	⁺ To whom correspondence should be addressed: jim.wilson@ed.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 Abstract

20	For breast and ovarian cancer risk assessment in the isolated populations of the Northern Isles of Orkney
21	and Shetland (in Scotland, UK) and their diasporas, quantifying genetically drifted BRCA1 and BRCA2
22	pathogenic variants is important. Two actionable variants in these genes have reached much higher
23	frequencies than in cosmopolitan UK populations. Here, we report a BRCA2 splice acceptor variant, c.517-
24	2A>G, found in breast and ovarian cancer families from Shetland. We investigated the frequency and
25	origin of this variant in a population-based research cohort of people of Shetland ancestry, VIKING I. The
26	variant segregates with female breast and ovarian cancer in diagnosed cases and is classified as
27	pathogenic. Exome sequence data from 2,108 participants with three or more Shetlandic grandparents in
28	VIKING I was used to estimate the population prevalence of c.517-2A>G in Shetlanders. Nine VIKING I
29	research volunteers carry this variant, on a shared haplotype (carrier frequency 0.4%). This frequency is
30	~130-fold higher than in UK Biobank, where the small group of carriers has a different haplotype. Records
31	of birth, marriage and death indicate genealogical linkage of VIKING I carriers to a founder from the Isle of
32	Whalsay, Shetland, similar to our observations for the BRCA1 founder variant from Westray, Orkney. In
33	total, 93.5% of pathogenic BRCA variant carriers in Northern Isles exomes are accounted for by these two
34	drifted variants. We thus provide the scientific evidence of an opportunity for screening people of
35	Orcadian and Shetlandic origins for each drifted pathogenic variant, particularly women with Westray or
36	Whalsay ancestry.

37

38 Keywords

39 Breast cancer, BRCA2, rare variants, isolate population

40 Introduction

41	Pathogenic variants in BRCA1 and BRCA2 confer a high lifetime risk of breast, ovarian and, for BRCA2,
42	male breast and prostate cancer (1-3). Genetic testing for disease-associated variants in these genes is
43	increasingly available as part of routine clinical care, to enable not only early detection and risk reduction,
44	but also to guide cancer treatment decisions. The genes are considered "tier 1" genes by the Centers for
45	Disease Control and Prevention Office of Public Health Genomics, on the basis that early detection of
46	pathogenic variants will have a positive effect on public health. Predictive testing of unaffected family
47	members is well established, with female pre-symptomatic carriers of pathogenic variants being offered
48	risk-reducing salpingo-oophorectomy and mastectomy, and early onset annual MRI breast screening.
49	Pathogenic variants in BRCA2 also increase risk of prostate cancer and male breast cancer (4), with male
50	pre-symptomatic carriers typically being offered prostate-specific antigen screening in the NHS.
51	Compellingly, the Icelandic p.Asn257LysfsTer17 founder variant in BRCA2 (previously termed 999del5 (5))
52	was associated with a shorter lifespan for both female carriers (effect of the variant, -9.3 years) and male
53	carriers (effect of the variant, -4.6 years) (6).
54	In isolate populations, a pathogenic variant present in a founding or early member can become more
55	frequent in later generations. Pathogenic variants in BRCA1 and BRCA2 that have drifted up in frequency
56	due to founder events have been described in many isolate and founder communities worldwide, notably
57	Ashkenazi and Sephardi Jews (7, 8), and Icelanders (5), as well as in larger populations (9).
58	The Northern Isles of Scotland – the Orkney and Shetland archipelagos - contain the most isolated of all
59	British and Irish populations, with the highest degree of Norse admixture. The genome-wide
60	distinctiveness revealed at common variants (10) is also reflected in the spectrum of rare and ultra-rare
61	variation: many such variants are enriched in the Shetlandic population (11). This pervasive genetic drift
62	also influences variants of clinical importance. Examples in the Northern Isles include a pathogenic BRCA1
63	founder variant that has drifted to high frequency in Orkney (12), and an actionable KCNH2 Long QT
64	Syndrome variant in Shetland (13). Here, we survey the landscape of pathogenic BRCA1, (MIM#113705)
65	BRCA2 (MIM#600185) and other breast cancer risk variants in the Northern Isles of Scotland.

The NHS Grampian clinical genetics team initially observed the BRCA2 splice acceptor variant, c.517-2A>G, 66 67 in breast and ovarian cancer cases from Shetland. The interpretation that this base substitution is a 68 pathogenic variant was demonstrated independently by multifactorial likelihood quantitative analysis 69 (definitely pathogenic, posterior probability 0.9994), together with co-segregation and tumour pathology 70 (14). The c.517-2A>G variant (also known as IVS6-2A>G) has been reported in multiple individuals affected 71 with Hereditary Breast and Ovarian Cancer worldwide, and is classed as pathogenic (reviewed by an 72 expert panel) in ClinVar (15), accession number VCV000051801. This BRCA2 variant lies in a canonical 73 splice acceptor site and is predicted using a range of tools to affect mRNA splicing, resulting in a 74 significantly altered protein due to exon skipping (16). Experimental evidence in vitro supports these 75 bioinformatic predictions (16, 17). 76 Viking Genes (viking.ed.ac.uk) comprises three cohort studies aiming to explore the genetic causes of 77 disease – the Orkney Complex Disease Study (ORCADES), VIKING I and VIKING II/III. VIKING I contains a 78 rich data resource of more than 2,000 deeply phenotyped and exome-sequenced research subjects with three or four grandparents from Shetland, whereas ORCADES is a similar-sized cohort of participants from 79 80 Orkney. Most recently, VIKING II/III is a worldwide cohort of 6,000 people, recruited online, with ancestry 81 from the Northern or Western Isles of Scotland (18). The UK Biobank is a cosmopolitan biomedical 82 database containing genetic, lifestyle and health information from half a million participants in the UK 83 (19). Here, we report the ascertainment of the BRCA2 pathogenic variant c.517-2A>G in both clinical care 84 in cancer families, and research volunteers, from Shetland. We investigate relatedness of the variant 85 carriers in Shetland using genealogy, infer origins, compare haplotypes in VIKING I and UK Biobank carrier participants and estimate population frequencies of pathogenic BRCA variants in Scottish island founder 86 87 populations both individually and collectively.

88

89 Materials and Methods

90 Genotyping

91 DNA from all VIKING I participants was used for genome-wide genotyping on the GSA BeadChip (Illumina)

92 at the Regeneron Genetics Center. Monomorphic genotypes and genotypes with more than 2% of

missingness and Hardy-Weinberg equilibrium (HWE) p<10⁻⁶ were removed, as well as individuals with
more than 3% of missingness. Details of genotyping, sample and variant quality control of UK Biobank
genotyping data are described in Bycroft *et al* (20).

96 DNA Sequencing and Annotation

97 The fully quality-controlled exome sequence data set of 2,108 VIKING I sequences (843 male and 1,265

98 female participants) passed all genotype quality control thresholds as described previously for the exomes

99 in the ORCADES cohort (12). The data was prepared at the Regeneron Genetics Center, following the

100 process detailed for UK Biobank (21). Details of the quality control of whole exome sequencing on the

101 200,000 participants from the UK Biobank are described in Backman *et al* (22). For Viking Genes, exonic

variants passing QC in BRCA1, BRCA2 and other cancer risk genes were filtered against ClinVar (15)

103 (accession date 28th March 2023) and Pathogenic/Likely Pathogenic variants were retained, irrespective

104 of star status. Pre-designed primers (Hs00585575, Thermo Fisher Scientific) were used to generate a PCR

105 fragment of 268 base pairs from genomic DNA for analysis. The BRCA2 c.517-2A>G, rs81002858 variant

106 was confirmed in VIKING I carriers by Sanger sequencing on an Applied Biosystems 3730xl Genetic

107 Analyser. All nine heterozygous variant calls from the VIKING I exome dataset were verified.

108 Haplotype analysis

109 The VIKING I array genotype data were phased using Shapeit2 v2r837 (23), with the duoHMM option that 110 uses the family-based nature of the data (24). Prior to phasing, the array genotype data were lifted over 111 from the genome build GRCh38 to GRCh37 using LiftOver, followed by quality control against the TOPMED 112 reference panel with Rayner's HRC-1000G-check-bim (v4.2.13) script that was downloaded from 113 https://www.well.ox.ac.uk/~wrayner/tools/. UK Biobank data were interrogated to ascertain the 114 frequency of the variant of interest. Details of phasing of UK Biobank genotyping data have been described (20). Then, the phased genotypes were used to determine a shared haplotype around c.517-115 116 2A>G using the fine method described previously (13). All methods were performed using R 4.0.2 (R Core 117 Team 2020 <u>https://www.R-project.org/</u>). Haplotypes were defined with custom-built in-house scripts in R. 118 Data handling was performed using data.table and tidyverse R packages. Plots were generated using

119 ggplot2.

120	A single variant-based haplotype search was performed to determine the haplotype length between the
121	different VIKING I carrier kindreds, and with the UK Biobank carrier individuals, using a stepwise approach.
122	Using phased genotype data, starting from the rs81002858 rare variant, one SNP at a time was added to
123	define a haplotype. The procedure was repeated until haplotypes of two individuals (both known carriers)
124	no longer matched, both upstream and downstream of the rare variant, providing variant-level resolution
125	of the haplotype length. The procedure was repeated for all pairs of individuals identified as carriers based
126	on the exome sequencing data, both in the VIKING I and UK Biobank datasets. The shortest shared
127	haplotype from VIKING I was then merged with the shortest shared haplotype from the UK Biobank, to
128	compare whether the haplotypes match.
129	EHR Data Linkage in VIKING I
130	NHS routine datasets linked to VIKING I participants in July 2021, including the Scottish Cancer Registry
131	SMR06, were accessed using a secure process, as described previously (12).
122	
132	
132	Results
	Results Clinical ascertainment of the BRCA2 c.517-2A>G variant
133	
133 134	Clinical ascertainment of the BRCA2 c.517-2A>G variant
133 134 135	Clinical ascertainment of the BRCA2 c.517-2A>G variant Eleven women from four Shetland families presenting with BRCA2-related cancers were found to have the
133 134 135 136	<i>Clinical ascertainment of the BRCA2 c.517-2A</i> >G <i>variant</i> Eleven women from four Shetland families presenting with <i>BRCA2</i> -related cancers were found to have the <i>BRCA2</i> c.517-2A>G variant, as part of routine clinical care. The family branches share some common
133 134 135 136 137	Clinical ascertainment of the BRCA2 c.517-2A>G variant Eleven women from four Shetland families presenting with BRCA2-related cancers were found to have the BRCA2 c.517-2A>G variant, as part of routine clinical care. The family branches share some common surnames, but the branches could not be genealogically linked. Two of the branches overlap
133 134 135 136 137 138	Clinical ascertainment of the BRCA2 c.517-2A>G variant Eleven women from four Shetland families presenting with BRCA2-related cancers were found to have the BRCA2 c.517-2A>G variant, as part of routine clinical care. The family branches share some common surnames, but the branches could not be genealogically linked. Two of the branches overlap genealogically with two VIKING I families with the same variant. To date, five of these 11 clinically
133 134 135 136 137 138 139	Clinical ascertainment of the BRCA2 c.517-2A>G variant Eleven women from four Shetland families presenting with BRCA2-related cancers were found to have the BRCA2 c.517-2A>G variant, as part of routine clinical care. The family branches share some common surnames, but the branches could not be genealogically linked. Two of the branches overlap genealogically with two VIKING I families with the same variant. To date, five of these 11 clinically ascertained carriers have had breast or ovarian cancer. Not all would have met the criteria for genetic
133 134 135 136 137 138 139 140	Clinical ascertainment of the BRCA2 c.517-2A>G variant Eleven women from four Shetland families presenting with BRCA2-related cancers were found to have the BRCA2 c.517-2A>G variant, as part of routine clinical care. The family branches share some common surnames, but the branches could not be genealogically linked. Two of the branches overlap genealogically with two VIKING I families with the same variant. To date, five of these 11 clinically ascertained carriers have had breast or ovarian cancer. Not all would have met the criteria for genetic testing in the mainstream NHS setting (see Supplementary Methods), without the context of the wider
133 134 135 136 137 138 139 140 141	Clinical ascertainment of the BRCA2 c.517-2A>G variant Eleven women from four Shetland families presenting with BRCA2-related cancers were found to have the BRCA2 c.517-2A>G variant, as part of routine clinical care. The family branches share some common surnames, but the branches could not be genealogically linked. Two of the branches overlap genealogically with two VIKING I families with the same variant. To date, five of these 11 clinically ascertained carriers have had breast or ovarian cancer. Not all would have met the criteria for genetic testing in the mainstream NHS setting (see Supplementary Methods), without the context of the wider family health history.

- 145 whom six are female. The Genome Aggregation Database (gnomAD v4.0) (25), containing over half a
- 146 million exomes from unrelated individuals, has 14 heterozygous carriers of the c.517-2A>G variant (Table

147	1). Consistent with this rarity, the variant is not observed in 2,090 participants in ORCADES (12). In good
148	agreement with gnomAD, 458,838 whole genome sequences from the UK Biobank (26) contain fifteen
149	instances (Table 1).
150	
151	We have access to exome sequence data from 200,000 individuals from UK Biobank, six of whom carry the
152	variant. These six were born and live in England, mostly in Yorkshire. Variant carriers are also reported in a
153	national UK repository of variants in cancer predisposition genes in cancer patients, CanVar-UK (27). There
154	are 35 carriers in this dataset (Table 1), five of whom are recorded as of non-European heritage. The
155	variant was also noted in one participant in a study of Japanese women with breast cancer (28).
156	Origin of the c.517-2A>G variant in Shetland

157 Three out of nine of the VIKING I variant carriers had all four grandparents born in the Isle of Whalsay, one

158 of the North Isles of Shetland, and five of them had at least one Whalsay grandparent. Of all 36

159 grandparents of the carriers, 14 (39%) were from Whalsay, with most of the remainder coming from other

parishes or isles of Shetland (Figure 1). The *BRCA2* pathogenic variant c.517-2A>G in Shetland thus shows

161 evidence of a founder from the parish of Whalsay.

162

Church records and data from the Scottish register of births, marriages and deaths traced six of the nine 163 164 research carriers to lineages with an origin in a couple born over 200 years ago on the island of Whalsay, 165 in the Shetland Isles (Figure 2). A further carrier descends from the same ancestral surname in the same 166 isle, potentially linking into the pedigree ~300 years ago (not shown), but the genealogical records do not 167 survive to prove the link. The c.517-2A>G families in the research cohort can thus be traced back to this 168 family, apart from two closely related carriers who have no genealogical links and no known ancestors 169 from Whalsay. This "Family B" is not shown in Figure 2, and is probably the result of an ancestral non-170 paternity event, given they share a haplotype with the main kindred and its outlier (see below). 171

172 c.517-2A>G carriers in VIKING I and UK Biobank do not share a common haplotype

173	All nine heterozygous c.517-2A>G carriers in VIKING I share the same haplotype around the variant locus,
174	with a minimum length of 3.6 Mb (Figure 3). Analysis of haplotypes in the genotype data from six UK
175	Biobank participants carrying the variant showed that all but one share a minimum ~0.7 Mb haplotype
176	around the variant. However, this was different to the Whalsay haplotype from VIKING I, and is noticeably
177	shorter: on average 1.4 Mb are shared vs. 9 Mb among the Shetlanders (excluding relatives closer than
178	fifth degree). The final UK Biobank carrier shares neither of these haplotypes.
179	
180	Penetrance of BRCA2 c.517-2A>G
181	Linkage to routine NHS data in the electronic health record (EHR) provides a longitudinal component to
182	the Viking Genes research cohorts, and affords the opportunity for unbiased penetrance estimates. All
183	nine c.517-2A>G carriers gave consent for EHR linkage, and the mean age of the six female carriers at time
184	of recruitment to VIKING I (baseline in 2013-2015) was 52. Analysis of the NHS cancer registry (SMR06)
185	dataset shows that one of the female c.517-2A>G carrier participants has a diagnosis of breast cancer, and
186	one of ovarian cancer. None of the other seven carriers (four females and three males) had any cancer
187	code recorded, or codes in the hospital admissions (SMR01) dataset for relevant risk-reducing surgery,
188	and all nine were alive in 2021. Volunteers also complete study questionnaire sections on family history of
189	disease, and this reveals that two obligate carriers – parents of participants, through which they link to
190	other carriers – were affected with cancer. One of these cancers (in a father) was non-Hodgkin's
191	lymphoma, for which there is some evidence of association with pathogenic variants in BRCA2 (29).
192	The landscape of BRCA1 and BRCA2 pathogenic variants in the Northern Isles
193	Apart from the two founder variants (<i>BRCA1</i> c.5207T>C; <i>BRCA2</i> c.517-2A>G), in our ~4,200-person
194	Northern Isles sample, only four other actionable BRCA variants are observed, all of them singletons in
195	BRCA2 (Supplementary Table 1). Two of these were inherited by participants from non-Northern Isles
196	parents, meaning that 93.5% of actionable BRCA variant carriers in Northern Isles genomes are accounted
197	for by the two drifted variants. One of the singletons inherited from outside the Isles (from a NE Scottish
198	Mainland-born parent) was the NE Scottish founder variant BRCA2 c.6275_6276del p.Leu2092fs (also

called 6503delTT; rs11571658 (30)). The other noted West Central Scottish founder variant, BRCA1

- 200 2800delAA (31), was absent from our cohorts.
- 201 Allele frequencies of founder BRCA variants

202 To explore further how common the drifted c.517-2A>G BRCA2 variant is across Shetland, we filtered our 203 population for people with four grandparents, and therefore their entire genome, from the Isle of 204 Whalsay. While there will be large confidence intervals, the point estimate of the carrier frequency is 205 2.3%, or one in 43 people from this isle, five-fold higher than in a general sample of Shetlanders, where 206 the carrier frequency is 1/234 (Table 2). For comparison, we have also analysed data from Orkney for the 207 drifted BRCA1 c.5207T>C variant, filtering for people with one or more grandparents from the Isle of 208 Westray, Orkney. The genetic drift is more extreme, with a carrier frequency estimate of 5.2% or 1 in 19 209 Westray genome equivalents, again five-fold higher than in a general sample of Orcadians. These 210 otherwise rare pathogenic alleles are therefore 700-2300 times more common in these isles than in the 211 general UK Biobank population (Table 2). For added context, numbers are also given in Table 2 for the 212 well-known Icelandic BRCA2 (6) and Ashkenazi Jewish BRCA1 and BRCA2 pathogenic alleles (7), with 213 carrier frequencies between 1 in 138 in Iceland and 1 in 41 for the combination of three variants in the 214 Ashkenazi community.

215

216 The frequency estimates of BRCA variants in the Northern Isles of Scotland are in total somewhat higher 217 than among women in the UK in general. For example, 1/293 women in UK Biobank are carriers of 218 pathogenic / likely pathogenic (with at least 2 star status in ClinVar) or predicted protein-truncating 219 variants in BRCA1/2 (32). Hence, the proportion carrying a potentially damaging BRCA variant in Orkney 220 (1/105) is more than twice that elsewhere in the UK. However, as shown in Table 2, it is when the 221 individual isle of origin is considered that the carrier frequencies rise an order of magnitude (e.g. 1/43 in 222 Whalsay, 1/19 in Westray), similar to the 1/41 observed for Ashkenazi Jews (three founder variants). 223 Other breast cancer susceptibility genes 224 Variants in the ataxia telangiectasia mutated gene ATM can increase the risk of breast cancer, though the gene is not on the ACMG v3.2 list of recommendations for reporting secondary findings in clinical exome 225

226 and genome sequencing (33). A pathogenic coding variant in ATM (c.7271T>G p.Val2424Gly; rs28904921, ClinVar VCV000003023) was described in an Orkney pedigree in 1998 (34), the "core" family. The variant is 227 228 rare but widespread globally, and case-control studies indicate it is strongly associated (OR~10) with 229 breast cancer (35, 36). In the ORCADES research cohort, we recovered the same previously reported 230 family (34). Beyond the previously reported three heterozygotes and three homozygotes, we identified 231 one further heterozygote closely related to this family. 232 Two further ATM p.Val2424Gly carriers were found, one is a seventh degree relative of the core family. In 233 total there are 6 alleles out of 4,180 sequenced in ORCADES = 0.14%. For comparison, in the UK Biobank 234 there are 91 alleles out of 917,638 European alleles sequenced = 0.0099%, thus there is a moderate uplift 235 in Orkney (~15-fold). We know from questionnaire data that a large number of first and second-degree 236 relatives of the carriers in the core family are alive but not in the ORCADES study, some of whom may

have volunteered to join the online study VIKING II (18). This may allow a better delineation of the size of

the kindred, and more accurate estimation of the frequency and any impact of the variant on breast

239 cancer risk in the Northern Isles of Scotland.

240 The relatively common loss-of-function c.1100del variant in CHEK2 (rs555607708, ClinVar VCV000128042) 241 imparts a moderate risk of breast and prostate cancer, even in individuals unselected for family history (37, 38). We observed only four heterozygous carriers of this variant, two from ORCADES and two from 242 243 VIKING I, giving an estimated minor allele frequency of 0.048% in the Northern Isles. This is five-fold lower 244 than the 0.24% seen in UK Biobank. It is notable that three of these four carriers in the Viking Genes 245 cohorts derive half their genomes from Lowland Scotland, and in one individual we know the allele must 246 have originated from the Scottish Mainland parent. This suggests c.1100del was rare-to-absent in the pre-247 WWII Northern Isles gene pool (due to genetic drift), but appears today due to post-WWII immigration from the rest of the British Isles. Like ATM, CHEK2 is not on the ACMG3.2 gene list of recommendations 248 249 for reporting incidental findings (33), but discussions related to the inclusion of further moderate 250 penetrance breast cancer genes, including both ATM and CHEK2, are ongoing (39); both of the above 251 variants are tested clinically in the UK, according to set guidelines (40).

252	No pathogenic exonic variants in other genes which confer an increased risk of breast cancer were
253	discovered: TP53, PALB2, STK11, PTEN – suggesting these are also essentially absent from the Northern
254	Isles gene pools. Moreover, none of the BRCA2 c.517-2A>G carriers in VIKING I also carry known
255	pathogenic exonic variants in the cancer susceptibility genes APC, BRCA1, RET, MAX, TMEM127, BMPR1A,
256	SMAD4, MLH1, MSH2, MSH6, PMS2, MEN1, MUTYH, NF2, SDHD, SDHAF2, SDHC, SDHB, RB1, VHL or WT1.
257	In the Northern Isles, the effects of random genetic drift over the centuries have thus simplified the
258	landscape of highly penetrant variants of large effect, such that two variants account for almost all of the
259	risk arising from rare pathogenic hereditary breast and ovarian cancer variants, while the impact of all
260	others is negligible. Clearly, high penetrance genes contribute only a proportion of genetic cancer risk,
261	whereas common low penetrance variants identified through genome-wide association studies explain a
262	further component, as of course do environmental exposures.
263	
264	Discussion
265	We recurrently identified the pathogenic <i>BRCA2</i> variant c.517-2A>G in the population of Shetland, both in
266	clinical practice and in a population cohort. The variant is found in ~0.4% of Shetlanders. All carriers in the
267	Shetland cohort VIKING I share the same haplotype background, which is distinct from that observed in
268	English UK Biobank carriers, pointing to recurrent mutation at the site. Genealogical analysis suggests the
269	variant is likely to have originated or arrived in a founder individual from Whalsay, Shetland, over 300
270	years ago. The presence of the same variant in a Japanese study, and in five non-white individuals in
271	CanVar, provides further evidence that this variant has arisen more than once worldwide.
272	Individuals not ascertained by cascade testing of relatives from the clinical pedigrees were identified in
273	the population-based sample. In previous work on the KCNH2 variant p.Gly584Ser (13), which increases
274	risk of long QT syndrome, and on BRCA1 p.Val1736Ala (12), we similarly identified carriers in our Northern
275	Isles research populations who could not have been ascertained from family-based cascade testing. This
276	highlights the value of research cohorts in uncovering rare clinical variants, which may in turn help
277	planning and implementation of genetic services. Our online cohort study, VIKING II, which has recruited
278	volunteers with Northern Isles grandparents irrespective of domicile (18), has highlighted scientifically for

the first time the extent of emigration. Significant Northern Isles diasporas are found in mainland

280 Scotland, former British colonies, particularly New Zealand, Canada and Australia, and also in England, all

locations where these alleles are therefore likely to be important for some families.

We show that the frequency estimates of pathogenic BRCA alleles in Orkney and Shetland are somewhat higher than those for women living in other areas of the UK. We have also demonstrated that variation in *ATM* and *CHEK2* does not contribute significantly to breast cancer in Orcadians. However, the overall

numbers affected by high penetrance variants will be low, given the modest population sizes. In the most

recent census for which data is available (2011), the population of Whalsay was 1,061 and of Westray,

287 588, while Shetland and Orkney had 23,167 and 21,279 inhabitants, respectively. The size of the extensive

diasporas is unknown. Given the combined population of over 64,000 in 1861 and the estimated number

of living descendants that would arise in line with European population growth rates in this period, we

speculate that the diasporas number in the hundreds of thousands, although the great majority will have

inherited only a fraction of their genomes from Northern Isles ancestors. Ongoing isolate breakdown, due

to continued immigration to the isles, but also increased within-archipelago migration and mixing, are

293 expected to similarly result in dilution of these high Northern Isles frequencies over time.

High penetrance BRCA1 and BRCA2 founder pathogenic variants have been described in several

295 populations such as the Ashkenazim, Icelanders, Poles, Norwegians and others (8). Testing for these

296 variants is increasingly well established in both clinical (<u>https://www.nhsjewishbrcaprogramme.org.uk/</u>)

and research (41) contexts and cost-effectiveness has been demonstrated in a number of settings. A

recent opinion paper addresses the routine failure to identify many monogenic cases of common diseases,

including breast and ovarian cancer, in clinical settings (42). It aims to focus attention on universal genetic

300 testing in common diseases for which the recommended clinical management of patients with monogenic

301 forms of disease diverges from standard management, and has evidence for improved outcomes. In a

302 step towards this, all women with a diagnosis of a high-grade serous ovarian carcinoma in Scotland

303 (https://www.sign.ac.uk/media/2010/sign135_oct2022.pdf) and Wales, UK, are now tested for

pathogenic *BRCA* variants, without the need for any family history (43, 44). Furthermore, those with

305 breast cancer under the age of 40, and triple negative breast cancer under 60, regardless of family history,

are widely tested in the UK (Supplementary Methods). However, the challenges of potential reduced
 penetrance in those without a known family history, and cost, have generally limited adoption of
 asymptomatic *BRCA1* and *BRCA2* screening.

309 Homozygosity for pathogenic BRCA2 variants causes a rare inherited form of bone marrow-associated 310 acute myeloid leukaemia, solid tumours and developmental anomalies termed Fanconi anaemia. We 311 estimate that the frequency of Fanconi anaemia in people with Whalsay grandparents could be as high as 312 1/10,000, considerably higher than the average for Europe of 4-7 per million (45). We propose that 313 awareness raising of this unlikely possibility in clinicians serving this population is important. 314 Single fragment Sanger sequencing for well characterised founder variants is considerably cheaper than 315 panel, whole exome or whole genome testing. Thus, testing efficiency would be likely to be considerably 316 higher in the Northern Isles of Scotland and their diaspora, as we have shown that ~93% of all actionable 317 variants in BRCA genes are accounted for by only two drifted variants. Furthermore, negligible numbers of 318 variants are segregating at other breast cancer risk genes. This is in sharp contrast with the 424 different 319 pathogenic or loss-of-function BRCA1/BRCA2 variants found in UK Biobank females, where 369 variants 320 account for 93% of all actionable variants (pers. comm. L. Jackson, University of Exeter, from analysis of 321 pathogenic variants as described in (32)). This considerable simplification of the gene pool in genetic 322 isolates, predicted to be an important factor in gene mapping study designs (46), may in fact be more 323 critical when considering genomic medicine screening in these populations. There is a case for offering all 324 Orcadian and Shetlandic women testing for the relevant drifted pathogenic BRCA variant, particularly 325 those with Westray or Whalsay ancestry. A pilot of self-administered saliva-based testing is underway for 326 the BRCA1 variant in Westray. Given current fiscal constraints and the somewhat lower frequency of the 327 Whalsay variant, the immediate recommendation is that testing for BRCA2 c.517-2A>G should be offered 328 to those of Whalsay ancestry with a first-degree relative with breast or ovarian cancer, and, to those with 329 an affected second degree relative connected through an unaffected male.

Currently, the consent framework of most research cohorts – including UK Biobank – does not allow the
 return of results about carrier status of actionable variants (21). However, participants in such studies
 often wish to receive results, particularly about "actionable" findings. This has stimulated publication of

333 an international policy for returning genomic research results (47), and a practical checklist for return of 334 results from genomic research in the European context (48). Others also recommend the return of results 335 following detection of hereditary breast and ovarian cancer risk to adult population-based biobank 336 participants (47, 49, 50). We have therefore invited ORCADES and VIKING I participants to consent to 337 return of results. In addition, our recent online cohort study VIKING II/III offered members the option of 338 consent to return of selected clinically actionable results at the point of joining, with an acceptance rate of 339 98% (18). Future research will explore additional genetically drifted loci in Orkney, Shetland and the 340 Western Isles of Scotland in the Viking Genes research cohorts, implement the return of results to 341 consented participants about actionable variants such as the drifted BRCA variants described here, and 342 evaluate the implementation of saliva-based BRCA testing of DNA in those of Westray and Whalsay 343 origins. 344 345 **Data Availability Statement** 346 There is neither Research Ethics Committee approval, nor consent from participants, to permit open 347 release of the individual level research data underlying this study. The datasets generated and analysed 348 during the current study are therefore not publicly available. Instead, the research data and/or DNA 349 samples are available from accessQTL@ed.ac.uk on reasonable request, via managed access, following

approval by the Data Access Committee and in line with the consent given by participants.

351 Acknowledgements

352 The study team wish to thank staff from the NHS Grampian genetics team and the Viking Genes Study for 353 their contribution to these datasets. DNA extractions were performed at the Edinburgh Clinical Research 354 Facility, University of Edinburgh. Sanger sequencing was performed by Camilla Drake and the technical 355 services team at the MRC HGU. Emily Weiss and Reka Nagy assembled the ORCADES pedigree, and 356 Barbara Gray the Shetland pedigree, using records at the General Register Office and study information, 357 building on earlier pedigree work by Ruth McQuillan and Jim Wilson. We thank Thibaud Boutin for phasing 358 the GSA chip data and Kiera Johnston for help with analysis of other cancer susceptibility genes. The data 359 in the EHR was provided by patients and collected by the NHS as part of their care and support. We would

also like to acknowledge the invaluable contributions of the research nurses in Orkney and Shetland and

- 361 the administrative team in Edinburgh, and the NHS Grampian genetic counselling team for counselling of
- the carriers identified in the cohorts. Finally, and most importantly, we thank the people of the Northern
- 363 Isles for their involvement in and ongoing support for our research.

364 Author Contribution Statement

- 365 SK managed the project and drafted the manuscript. LK analysed the exome datasets. MM and LK did the
- haplotype comparisons. EC and LS provided de-identified clinical data. GT and ARS conceived and
- 367 managed the Viking Genes exome sequencing. ZM recognised carrier patients through the NHS Grampian
- 368 clinical genetics service, led clinical aspects of return of results planning and proposed policy. JFW is the
- 369 Chief Investigator of Viking Genes, was awarded funding to implement the work, did genealogical
- analyses, interpreted the data and helped draft the manuscript. All authors provided input and feedback
- on drafts of the manuscript.
- 372 Funding

373 This work was funded by the MRC University Unit award to the MRC Human Genetics Unit, University of

- 374 Edinburgh, MC_UU_00007/10 and a Wellcome Trust Institutional Translational Partnership Award
- 375 (University of Edinburgh 222060/Z/20/Z -PIII031). LK was supported by an RCUK Innovation Fellowship
- 376 from the National Productivity Investment Fund (MR/R026408/1).

377 Ethical Approval

378 Eligible participants were recruited to ORCADES and the Viking Health Study Shetland (VIKING I), now part 379 of Viking Genes, Research Ethics Committee reference 19/SS/0104. Research participants gave written 380 informed consent for research procedures that included electronic health record linkage and DNA 381 sequencing. The data linkage and access to NHS Scotland-originated data for ORCADES and VIKING I was 382 approved by the Public Benefit and Privacy Panel for Health and Social Care (Ref 1718-0380). This research 383 has also been conducted using data from UK Biobank, as part of project number 19655. Frequencies for 384 the ATM and CHEK2 variants reported here, and the BRCA2 variant c.517-2A>G numbers in Table 1, were 385 derived from the UK Biobank Whole Genome Sequencing (WGS) project and were obtained from the UK

- 386 Biobank Allele Frequency Browser (afb.ukbiobank.ac.uk), which was generated by the WGS consortium
- 387 under the UK Biobank Resource (project ID 52293).
- 388

389 Competing Interests

- 390 AS and GT are employees and/or stockholders of Regeneron Genetics Center or Regeneron
- 391 Pharmaceuticals.
- 392
- 393 For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to
- any Author Accepted Manuscript version arising from this submission.
- 395

396 References

- 397 1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast
- 398 and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for
- family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-30.
- 400 2. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of
- 401 Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA.
- 402 2017;317(23):2402-16.
- 403 3. Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, et al. BRCA Challenge: BRCA
- 404 Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018;14(12):e1007752.
- 405 4. Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer Risks Associated With
- 406 BRCA1 and BRCA2 Pathogenic Variants. J Clin Oncol. 2022;40(14):1529-41.
- 407 5. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, et al. Study
- 408 of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet.
- 409 1997;60(5):1079-84.
- 410 6. Jensson BO, Arnadottir GA, Katrinardottir H, Fridriksdottir R, Helgason H, Oddsson A, et al.
- 411 Actionable Genotypes and Their Association with Life Span in Iceland. N Engl J Med. 2023;389(19):1741-
- 412 52.

- 413 7. Hamel N, Kotar K, Foulkes WD. Founder mutations in BRCA1/2 are not frequent in Canadian
- 414 Ashkenazi Jewish men with prostate cancer. BMC Med Genet. 2003;4:7.
- 415 8. Rubinstein WS. Hereditary breast cancer in Jews. Fam Cancer. 2004;3(3-4):249-57.
- 416 9. Abul-Husn NS, Soper ER, Odgis JA, Cullina S, Bobo D, Moscati A, et al. Exome sequencing reveals a
- 417 high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome
- 418 Med. 2019;12(1):2.
- 419 10. Gilbert E, O'Reilly S, Merrigan M, McGettigan D, Vitart V, Joshi PK, et al. The genetic landscape of
- 420 Scotland and the Isles. Proc Natl Acad Sci U S A. 2019;116(38):19064-70.

421 11. Halachev M, Meynert A, Taylor MS, Vitart V, Kerr SM, Klaric L, et al. Increased ultra-rare variant

- 422 load in an isolated Scottish population impacts exonic and regulatory regions. PLoS Genet.
- 423 2019;15(11):e1008480.
- 424 12. Kerr SM, Cowan E, Klaric L, Bell C, O'Sullivan D, Buchanan D, et al. Clinical case study meets
- 425 population cohort: identification of a BRCA1 pathogenic founder variant in Orcadians. Eur J Hum Genet.
 426 2023;31(5):588-95.
- 427 13. Kerr SM, Klaric L, Halachev M, Hayward C, Boutin TS, Meynert AM, et al. An actionable KCNH2
- 428 Long QT Syndrome variant detected by sequence and haplotype analysis in a population research cohort.
- 429 Sci Rep. 2019;9(1):10964.
- 430 14. Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadalo L, et al. Large scale
- 431 multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to
- 432 support clinical variant classification. Hum Mutat. 2019;40(9):1557-78.
- 433 15. Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, et al. ClinVar: improvements to
- 434 accessing data. Nucleic Acids Res. 2020;48(D1):D835-D44.
- 435 16. Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, et al. Guidelines for
- 436 splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on
- 437 BRCA1 and BRCA2 variants. Hum Mutat. 2012;33(8):1228-38.

- 438 17. Casadei S, Gulsuner S, Shirts BH, Mandell JB, Kortbawi HM, Norquist BS, et al. Characterization of
- 439 splice-altering mutations in inherited predisposition to cancer. Proc Natl Acad Sci U S A.
- 440 2019;116(52):26798-807.
- 18. Kerr S, Edwards R, Buchanan D, Dean J, Miedzybrodzka Z, Wilson J. VIKING II, a Worldwide
- 442 Observational Cohort of Volunteers with Northern Isles Ancestry. International Journal of Population Data
- 443 Science. 2023;8(1).
- 444 19. Allen NE, Lacey B, Lawlor DA, Pell JP, Gallacher J, Smeeth L, et al. Prospective study design and
- data analysis in UK Biobank. Sci Transl Med. 2024;16(729):eadf4428.
- 446 20. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with
- deep phenotyping and genomic data. Nature. 2018;562(7726):203-9.
- 448 21. Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, et al. Exome sequencing
- and characterization of 49,960 individuals in the UK Biobank. Nature. 2020;586(7831):749-56.
- 450 22. Backman JD, Li AH, Marcketta A, Sun D, Mbatchou J, Kessler MD, et al. Exome sequencing and
- 451 analysis of 454,787 UK Biobank participants. Nature. 2021;599(7886):628-34.
- 452 23. Delaneau O, Howie B, Cox AJ, Zagury JF, Marchini J. Haplotype estimation using sequencing reads.
- 453 Am J Hum Genet. 2013;93(4):687-96.
- 454 24. O'Connell J, Gurdasani D, Delaneau O, Pirastu N, Ulivi S, Cocca M, et al. A general approach for
- 455 haplotype phasing across the full spectrum of relatedness. PLoS Genet. 2014;10(4):e1004234.
- 456 25. Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genome-wide mutational
- 457 constraint map quantified from variation in 76,156 human genomes. bioRxiv. 2022:2022.03.20.485034.
- 458 26. Li S, Carss KJ, Halldorsson BV, Cortes A, Consortium UBW-GS. Whole-genome sequencing of half-a-
- 459 million UK Biobank participants. medRxiv. 2023:2023.12.06.23299426.
- 460 27. Chubb D, Broderick P, Dobbins SE, Houlston RS. CanVar: A resource for sharing germline variation
- 461 in cancer patients. F1000Res. 2016;5:2813.
- 462 28. Liu Y, Ide Y, Inuzuka M, Tazawa S, Kanada Y, Matsunaga Y, et al. BRCA1/BRCA2 mutations in
- 463 Japanese women with ductal carcinoma in situ. Mol Genet Genomic Med. 2019;7(3):e493.

464 29. Usui Y, Iwasaki Y, Matsuo K, Endo M, Kamatani Y, Hirata M, et al. Association between germline

465 pathogenic variants in cancer-predisposing genes and lymphoma risk. Cancer Sci. 2022;113(11):3972-9.

466 30. Scottish/Northern Irish BBC. BRCA1 and BRCA2 mutations in Scotland and Northern Ireland. Br J

467 Cancer. 2003;88(8):1256-62.

468 31. Liede A, Cohen B, Black DM, Davidson RH, Renwick A, Hoodfar E, et al. Evidence of a founder

469 BRCA1 mutation in Scotland. Br J Cancer. 2000;82(3):705-11.

470 32. Jackson L, Weedon MN, Green HD, Mallabar-Rimmer B, Harrison JW, Wood AR, et al. Influence of

471 family history on penetrance of hereditary cancers in a population setting. EClinicalMedicine.

472 2023;64:102159.

473 33. Miller DT, Lee K, Abul-Husn NS, Amendola LM, Brothers K, Chung WK, et al. ACMG SF v3.2 list for

474 reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the

475 American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(8):100866.

476 34. Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, et al. ATM mutations and

477 phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of

478 leukemia, lymphoma, and breast cancer. Am J Hum Genet. 1998;62(2):334-45.

479 35. Southey MC, Goldgar DE, Winqvist R, Pylkas K, Couch F, Tischkowitz M, et al. PALB2, CHEK2 and

480 ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016;53(12):800-11.

481 36. Moslemi M, Moradi Y, Dehghanbanadaki H, Afkhami H, Khaledi M, Sedighimehr N, et al. The

association between ATM variants and risk of breast cancer: a systematic review and meta-analysis. BMC

483 Cancer. 2021;21(1):27.

484 37. Woodward ER, van Veen EM, Forde C, Harkness EF, Byers HJ, Ellingford JM, et al. Clinical utility of

testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Genet Med. 2021;23(10):1969-76.

486 38. Loveday C, Garrett A, Law P, Hanks S, Poyastro-Pearson E, Adlard JW, et al. Analysis of rare

487 disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-

488 impact susceptibility genes. Ann Oncol. 2022;33(12):1318-27.

- 489 39. Miller DT, Lee K, Abul-Husn NS, Amendola LM, Brothers K, Chung WK, et al. ACMG SF v3.1 list for
- 490 reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the
- 491 American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022;24(7):1407-14.
- 492 40. Evans DG, Green K, Burghel GJ, Forde C, Lalloo F, Schlecht H, et al. Cascade screening in HBOC and
- 493 Lynch syndrome: guidelines and procedures in a UK centre. Familial Cancer. 2024.
- 494 41. Stefansdottir V, Thorolfsdottir E, Hognason HB, Patch C, van El C, Hentze S, et al. Web-based
- 495 return of BRCA2 research results: one-year genetic counselling experience in Iceland. Eur J Hum Genet.
- 496 2020;28(12):1656-61.
- 497 42. Murray MF, Khoury MJ, Abul-Husn NS. Addressing the routine failure to clinically identify
- 498 monogenic cases of common disease. Genome Med. 2022;14(1):60.
- 499 43. Rust K, Spiliopoulou P, Tang CY, Bell C, Stirling D, Phang T, et al. Routine germline BRCA1 and
- 500 BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience. BJOG.
- 501 2018;125(11):1451-8.
- 502 44. Kansu B, Gardner J, Price-Tate R, Murch O, Murray A. BRCA gene testing in women with high-

503 grade serous ovarian carcinoma. J Obstet Gynaecol. 2021;41(6):962-5.

- 504 45. Gulbis B, Eleftheriou A, Angastiniotis M, Ball S, Surralles J, Castella M, et al. Epidemiology of rare 505 anaemias in Europe. Adv Exp Med Biol. 2010;686:375-96.
- 506 46. Wright AF, Carothers AD, Pirastu M. Population choice in mapping genes for complex diseases.
- 507 Nat Genet. 1999;23(4):397-404.
- 47. Lewis ACF, Knoppers BM, Green RC. An international policy on returning genomic research results.
 Genome Med. 2021;13(1):115.
- 48. Vears DF, Hallowell N, Bentzen HB, Ellul B, Nost TH, Kerasidou A, et al. A practical checklist for
- return of results from genomic research in the European context. Eur J Hum Genet. 2023;31(6):687-95.
- 512 49. Leitsalu L, Palover M, Sikka TT, Reigo A, Kals M, Pärn K, et al. Genotype-first approach to the
- 513 detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank
- participants. European Journal of Human Genetics. 2021;29(3):471-81.

- 515 50. Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, et al. Exome
- 516 Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank
- 517 Participants. JAMA Network Open. 2018;1(5):e182140-e.

519 Figure and Table Legends


520	Figure 1. Grandparental ancestry of BRCA2 c.517-2A>G carriers in VIKING I. The first seven bars are
521	parishes or isles of Shetland. The remainder are locations elsewhere in the UK. Of all 36 grandparents of
522	the carriers, 14 (39%) were from Whalsay, with most of the remainder coming from other parishes or isles
523	of Shetland.
524	
525	Figure 2. Outline pedigree of a large kindred from the VIKING I study. The founder of the kindred was
526	born in Whalsay in 1786, and all descendants enclosed by the blue line were also born there. He had
527	children by two wives. Red outlines are sequenced BRCA2 c.517-2A>G carriers in VIKING I, dotted red
528	outlines are obligate carriers (parents of carriers, who link to other carriers). Sequenced VIKING I
529	participants without the variant are shown in green. There are many other family members not shown.
530	
531	Figure 3. Visualisation of haplotype sharing across nine Shetland carriers. The phased Illumina GSA chip
532	genotypes across an 8 Mb region on chromosome 13 are represented for one haplotype from each
533	individual. The pathogenic variant is at 32.33 Mb and a multi-Mb identical-by-descent block is apparent in
534	the centre of the plot. For close relatives, the extent of sharing goes beyond the window shown. Mb,
535	megabase.
536	
537	Table 1. Frequencies of BRCA2 c.517-2A>G carriers in genomic datasets. The numbers of carriers are
538	reported for diverse genomic datasets. gnomAD, genome aggregation database; CanVar-UK, Cancer
539	Predisposition Gene Variant Database.
540	
541	Table 2. Carrier frequency estimates of BRCA founder variants in the Northern Isles of Scotland and
542	comparison populations. UKB-EU, UK Biobank European-heritage, exome data reported by CanVar-UK
543	v2.2 release date July 2023 (27). Westray estimates use data from ORCADES on n=1461 self-reported
544	Westray-born grandparents, or 365.25 full Westray genome equivalents. Whalsay estimates use VIKING I
545	individuals with all four grandparents born in Whalsay. N, number of carriers. "One in" gives the reciprocal


546	of the carrier frequency, e.g. one in 105 individuals. Allele frequencies are half the carrier frequencies, for
547	variants such as these, where no homozygotes are observed. Uplift presents the fold uplift in frequency
548	over and above that in UK Biobank European-heritage. The total number of individuals for the sum of the
549	three Ashkenazi founder variants is taken as the average of the counts for the three individual variants.
550	BRCA2 517-2A>G is rs81002858; BRCA1 c.5207T>C is rs45553935; BRCA2 c.771_775 del is rs80359671;
551	BRCA1 c.68_69del is rs80357914; BRCA1 c.5266dup is rs80357906; BRCA2 c.5946del is rs80359550.
552	
553	Supplementary Table 1 Actionable BRCA1/2 variants in Orkney and Shetland. Pathogenic or likely
554	pathogenic variants in BRCA1 or BRCA2 among 4198 exomes from the Northern Isles. All six variants have
555	3* status in ClinVar as pathogenic and were reviewed by an expert panel, all are autosomal dominant. c.
556	gives the coding DNA position and change; p, the protein position and change; rsid, reference SNP cluster


557 ID; GRCh38, Genome Reference Consortium human build 38; LOF, loss of function.

Dataset	Description	Number of Individuals	Carriers of BRCA2 c.517-2A>G variant	Non-European Carriers
gnomAD v4.0	Unrelated European (non-Finnish) individuals from genetic studies	549,120 exome sequences	14	0
Viking Health Study Shetland (VIKING I)	Isolate population cohort from Shetland, UK	2,108 exome sequences	9	0
Orkney Complex Disease Study (ORCADES)	Visease Study		0	0
UK Biobank	Cosmopolitan population cohort from UK	458,838 whole genome sequences	15	0
CanVar-UK	Sequenced cancer genes of NHS cancer patients England & Wales	80,722 total probands tested	35	5
Japanese women with breast cancer	omen with BRCA1 and BRCA2 genes		1	1

Table 1. Frequencies of *BRCA2* c.517-2A>G carriers in genomic datasets.







Variant	Population	Ν	Total	Frequency	%	One in	Uplift	Reference
BDCA3	UKB-EU	14	432,222	3.24E-05	0.0032	30,873		27
<i>BRCA2</i> c.517-2A>G	Shetlanders	9	2108	0.0043	0.43	234	132	current study
C.517-2A/G	Whalsay	3	129	0.023	2.3	43	718	current study
22644	UKB-EU	10	442,259	2.26E-05	0.0023	44,226		27
<i>BRCA1</i> c.5207T>C	Orcadians	20	2090	0.0096	0.96	105	423	3
0.5207120	Westray	19	365.25	0.052	5.2	19	2301	current study
<i>BRCA2</i> c.771_775del (999del5)	Icelanders	421	57,933	0.0073	0.73	138		14
<i>BRCA1</i> c.68_69del (185delAG)	Ashkenazi Jews	85	9371	0.0091	0.91	110		15
<i>BRCA1</i> c.5266dup (5382insC)	Ashkenazi Jews	24	8867	0.0027	0.27	369		15
<i>BRCA2</i> c.5946del (6174delT)	Ashkenazi Jews	119	9514	0.012	1.2	80		15
3 Ashkenazi founder variants	Ashkenazi Jews	228	~9250	0.024	2.4	41		15

Table 2. Carrier frequency estimates of BRCA founder variants in the Northern Isles of Scotland

and comparison populations.